Bharat Immunological & Biological Corporation Ltd
₹ 16.8
-1.99%
30 Jun
- close price
About
Incorporated in 1989, Bharat Immunological and Biologicals Corporation Ltd manufactures biotechnology-based pharmaceuticals.[1]
Key Points
- Market Cap ₹ 72.4 Cr.
- Current Price ₹ 16.8
- High / Low ₹ 24.3 / 14.1
- Stock P/E
- Book Value ₹ 18.2
- Dividend Yield 0.00 %
- ROCE -9.27 %
- ROE -17.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.92 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.09% over past five years.
- Company has a low return on equity of -22.7% over last 3 years.
- Debtor days have increased from 39.6 to 114 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46 | 173 | 203 | 146 | 128 | 124 | 35 | 84 | 67 | 85 | 78 | 45 | 8 | |
| 41 | 164 | 191 | 143 | 132 | 111 | 43 | 93 | 77 | 106 | 83 | 63 | 25 | |
| Operating Profit | 6 | 9 | 12 | 3 | -4 | 13 | -8 | -9 | -10 | -21 | -5 | -18 | -18 |
| OPM % | 12% | 5% | 6% | 2% | -3% | 10% | -23% | -11% | -16% | -24% | -6% | -41% | -232% |
| 2 | 1 | 6 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 1 | 3 | 1 | |
| Interest | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 2 | 5 | 5 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 6 | 7 | 11 | 2 | -9 | 9 | -8 | -7 | -14 | -24 | -10 | -23 | -25 |
| Tax % | -111% | 27% | 42% | 26% | -31% | 29% | -46% | -21% | -28% | -25% | -10% | -25% | |
| 13 | 5 | 6 | 2 | -6 | 7 | -4 | -6 | -10 | -18 | -9 | -17 | -18 | |
| EPS in Rs | 2.91 | 1.16 | 1.48 | 0.36 | -1.44 | 1.51 | -0.99 | -1.34 | -2.36 | -4.19 | -2.03 | -3.95 | -4.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | 5% |
| 3 Years: | -13% |
| TTM: | -90% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -31% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -25% |
| 3 Years: | -10% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -24% |
| 3 Years: | -23% |
| Last Year: | -18% |
Balance Sheet
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| Reserves | -15 | -1 | -3 | -2 | -8 | -1 | -6 | -12 | -23 | -9 | 62 | 45 | 36 |
| 7 | 0 | -1 | -9 | 9 | 0 | 0 | 32 | 3 | 27 | 78 | 70 | 74 | |
| 45 | 48 | 52 | 48 | 24 | 17 | 16 | 62 | 103 | 43 | 29 | 28 | 35 | |
| Total Liabilities | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
| 9 | 8 | 7 | 6 | 6 | 5 | 5 | 5 | 4 | 4 | 116 | 115 | 115 | |
| CWIP | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 71 | 82 | 84 | 74 | 63 | 53 | 48 | 120 | 122 | 68 | 97 | 70 | 73 | |
| Total Assets | 81 | 90 | 91 | 80 | 68 | 59 | 53 | 125 | 127 | 104 | 213 | 186 | 188 |
Cash Flows
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 31 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 | |
| -0 | 0 | 0 | 0 | 1 | 0 | -1 | 1 | 1 | 1 | 1 | 0 | |
| -3 | -0 | -6 | -1 | -2 | -3 | -1 | 31 | -34 | -12 | 45 | -15 | |
| Net Cash Flow | 2 | 31 | -18 | 7 | -10 | -20 | 1 | -1 | 1 | 0 | 3 | -3 |
| Free Cash Flow | 5 | 32 | -12 | 8 | -9 | -17 | 3 | -32 | 34 | 12 | -42 | 11 |
| CFO/OP | 89% | 338% | -99% | 229% | 239% | -132% | -32% | 344% | -328% | -56% | 847% | -59% |
Ratios
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 209 | 2 | 47 | 34 | 37 | 19 | 167 | 318 | 96 | 0 | 5 | 114 |
| Inventory Days | 241 | 87 | 66 | 84 | 77 | 2 | 23 | 67 | 308 | 56 | 202 | 13 |
| Days Payable | 316 | 99 | 70 | 103 | 26 | 1 | 6 | 204 | 259 | 61 | 5 | 4 |
| Cash Conversion Cycle | 134 | -9 | 43 | 16 | 88 | 19 | 185 | 181 | 145 | -5 | 203 | 122 |
| Working Capital Days | -20 | -20 | 21 | 20 | 28 | -19 | 59 | 10 | -108 | -174 | -227 | -549 |
| ROCE % | 20% | 23% | 42% | 9% | -8% | 31% | -18% | -11% | -22% | -46% | -3% | -9% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|
| Electricity Consumption for OPV Production Units (kWh) |
|
|||
| Electricity Consumption Rate per Lakh Doses (OPV) Units / 1,00,000 Doses |
||||
| Employee Benefit Expenses INR Lakhs |
||||
| Revenue from Operations - Oral Polio Vaccine (OPV) INR Lakhs |
||||
| Revenue from Sales - Zinc Tablets INR Lakhs |
||||
| Revenue from Sales - BIBSANIT (Sanitizer) INR Lakhs |
||||
| Land Holding (OPV Plant) Acres |
||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 16.08.2024 Under Regulation 29 Of SEBI'S LODR.
7 Aug 2024 - Board meeting scheduled for August 16, 2024.
-
Board Meeting Intimation for Intimation Of Date Of Board Meeting On 08.03.2024 Under Regulation 29 Of SEBI'S LODR.
29 Feb 2024 - Board meeting scheduled for March 8, 2024.
- Compliance Of Regulation 34 Of LODR 2015 And Submission Annual Report For 34Th Annual General Meeting Scheduled On 29.12.2023. 13 Dec 2023
- Compliance Of The Regulation Of LODR 2015 For The Intimation Of Book Closure Period (22.12.2023 To 29.12.2023) Of The Company In Respect Of 34Th Annual General Meeting Scheduled To Be Held On 29.12.2023. 28 Nov 2023
- Submission Of Notice Of 34Th Annual General Meeting On 29.12.2023 As Compliance Of The Provision Of LODR 2015. 28 Nov 2023
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1][2]
BIBCL is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India, undertaking. It was established as a Public Sector Unit to achieve the production and supply of high-quality polio vaccine. The company had captured 60% of the total market share and was among the top 20 Biotech companies in Indiain India. Currently, it manufactures and produces a range of pharmaceutical products such as:
a) Oral Polio Vaccines (OPV Vaccine)
b) Diarrhea Management Kits
c) BIB Sweet Tablets
d) Hepatitis B vaccine
e) Zinc Tablets, etc.
In FY16, the company switched over to bOPV from tOPV. To add in product line, the company diversified into plasma-derived medicines and the Oral Cholera Vaccine.